<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221636</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-278</org_study_id>
    <nct_id>NCT01221636</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept</brief_title>
  <official_title>A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the blood levels of abatacept drug product
      manufactured using High Metals and using Low Metals are comparable in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the pharmacokinetic (PK) of High Metals abatacept relative to Low Metals abatacept
      following a single intravenous infusion of 750 mg in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-dose pharmacokinetic parameters: Cmax (Maximum observed serum concentration)</measure>
    <time_frame>Over 71 days after single dose administered</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose pharmacokinetic parameters: AUC 0-71 days (Area under the serum concentration-time curve from time zero to 71 days)</measure>
    <time_frame>Over 71 days after single dose administered</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose pharmacokinetic parameters: AUC (INF) (Area under the serum concentration-time curve from time zero extrapolated to infinity)</measure>
    <time_frame>Over 71 days after single dose administered</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity determination will be based on titers of anti abatacept and anti-CTLA-4-T antibodies in serum over time</measure>
    <time_frame>Days 29, 57, and 71 after single dose administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments: adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests. The incidence of observed adverse events will be tabulated and reviewed for potential significance and clinical importance</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 22, 29, 43, 57 and 71 after single dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Low Metal Abatacept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Metal Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Solution for injection, Intravenous, 750 mg, 1 day</description>
    <arm_group_label>Low Metal Abatacept</arm_group_label>
    <arm_group_label>High Metal Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body weight will be between 60 and 100 kg, inclusive

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Any major surgery within 4 weeks of study drug administration

          -  Smoking more than 10 cigarettes per day

          -  Recent (within 6 months of study drug administration) drug or alcohol abuse

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1,
             -2 antibody

          -  History of any significant drug allergy or asthma

          -  Women who are pregnant or breastfeeding and/or unwilling or unable to use an
             acceptable method to avoid pregnancy for the entire study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

